Increasing Treatment Options for Gastrointestinal Stromal Tumors
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors.
Progress Against Cancer
The FDA has approved a new molecularly targeted therapeutic for treating certain patients who have advanced gastrointestinal stromal tumors.
The FDA has expanded the use of a molecularly targeted therapeutic to include the treatment of certain patients with prostate cancer.
The FDA has approved a combination of the immunotherapeutics nivolumab and ipilimumab to treat certain patients with metastatic lung cancer.
The FDA has expanded the use of an immunomodulatory therapeutic to include the treatment of adults who have Kaposi sarcoma.
The FDA has approved an alternative dosing schedule for the immune checkpoint inhibitor pembrolizumab.
The FDA approved a new molecularly targeted therapeutic for certain patients with lung cancer driven by a mutation in the MET gene.
The FDA approved a type of molecularly targeted therapeutic called an antibody-drug conjugate for the treatment of metastatic triple-negative breast cancer.
The FDA has approved a new molecularly targeted therapeutic for treating certain patients with advanced or metastatic HER2-positive breast cancer.
The first molecularly targeted therapeutic for use in the treatment of bile duct cancer has been approved by the FDA.
Treating a rare cancer with a chemotherapy gel.
AACR Fellow Lewis C. Cantley, PhD, leads a national effort targeting triple-negative breast cancer and ovarian cancer with a novel drug combination.
Learn MoreYour donation to the American Association for Cancer Research helps our more than 58,000 members worldwide drive progress against cancer.
Donate Now